CN112225797B - Monoclonal antibody for resisting SARS-CoV-2 nucleocapsid protein and application thereof - Google Patents

Monoclonal antibody for resisting SARS-CoV-2 nucleocapsid protein and application thereof Download PDF

Info

Publication number
CN112225797B
CN112225797B CN202011019047.4A CN202011019047A CN112225797B CN 112225797 B CN112225797 B CN 112225797B CN 202011019047 A CN202011019047 A CN 202011019047A CN 112225797 B CN112225797 B CN 112225797B
Authority
CN
China
Prior art keywords
cov
sars
monoclonal antibody
kit
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011019047.4A
Other languages
Chinese (zh)
Other versions
CN112225797A (en
Inventor
陆绍红
孔庆明
丁豪杰
丁建祖
高孟
卓洵辉
谢承作
袁亚杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Medical College
Original Assignee
Hangzhou Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Medical College filed Critical Hangzhou Medical College
Priority to CN202011019047.4A priority Critical patent/CN112225797B/en
Publication of CN112225797A publication Critical patent/CN112225797A/en
Application granted granted Critical
Publication of CN112225797B publication Critical patent/CN112225797B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention discloses a monoclonal antibody of anti-SARS-CoV-2 nucleocapsid protein and its application. The monoclonal antibody comprises a light chain and a heavy chain, and is characterized in that the amino acid sequences of the variable region CDR1, CDR2 and CDR3 of the light chain are RASENIYSSLA, VATDLA and QHFWGTPWT respectively; the heavy chain variable region CDR1, CDR2 and CDR3 have amino acid sequences of TDHYII, EIYPGNGHTYNERFKG and SRYYGPFAYWG, respectively. The monoclonal antibody of the invention for resisting SARS-CoV-2 nucleocapsid protein is IgG1 subtype, and the affinity of the antibody can reach 5.28X 10‑11The kit has the advantages of strong immunocompetence, good stability, high activity, strong affinity and the like, has strong detection specificity, high sensitivity and good accuracy, can be used in a kit of a full-automatic immunoassay analyzer, is also applied to immunochromatography test paper strips for detecting SARS-CoV-2 nucleocapsid protein, and can effectively promote the popularization and application of SARS-CoV-2 detection.

Description

Monoclonal antibody for resisting SARS-CoV-2 nucleocapsid protein and application thereof
Technical Field
The invention relates to the field of biotechnology, in particular to a monoclonal antibody for resisting SARS-CoV-2 nucleocapsid protein and application thereof.
Background
The novel coronavirus pneumonia is a novel respiratory disease caused by severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2). SARS-CoV-2 is a seventh positive-stranded RNA virus capable of infecting humans with an envelope. The genomics identification of SARS-CoV-2 shows that it is a binuclear virus with 96% homology to RaTG13, but different from SARS-CoV. SARS-CoV-2 has a Receptor Binding Domain (RBD) structure similar to that of SARS-CoV. The functional Open Reading Frame (ORF) of SARS-CoV-2 comprises ORF1a and ORF1b, and the major structural proteins include spike protein (S), membrane protein (M), envelope protein (E) and nucleocapsid protein (N). According to prior studies, the M and E proteins are essential for viral assembly. The S protein is associated with viral adhesion to host cells, where the RBD structure of the S protein mediates the interaction with angiotensin enzyme 2. The S protein is localized to the surface of the viral particle and is highly immunogenic. One of the major structures of N protein viruses, involved in transcription and replication of viral RNA, functions to package the viral genome into virions and interfere with the cellular cycle. In many coronaviruses, including SARS-CoV, the N protein is highly immunogenic and is expressed in large quantities during infection. The S and N proteins are therefore potential antigens for COVID-19 serological diagnosis.
At present, COIVD-19 is mainly diagnosed by detecting viral RNA by real-time quantitative PCR (RT-PCR). Studies have shown that SARS-CoV-2 primarily infects the lower respiratory tract, as detected by nasopharyngeal swabs and samples of the bronchi. However, the collection of lower airway samples requires specialized equipment and skilled personnel. Previous studies show that the positive rate of sputum samples of patients confirmed by RT-PCR is 74.4% -88.9%; the positive rate of the nasal swab sample is 53.6-73.3%; pharyngeal swabs more than 8 days after onset have a very low positive rate. Since the main site of viral infection is in the lower respiratory tract, the different respiratory tract samples collected give rise to a high negative rate. Therefore, there is a strong need for an accurate and efficient detection method for evaluating patients with suspected symptoms.
The invention with publication number CN111187354A discloses a test paper for detecting SARS-CoV-2 antibody by colloidal gold capture method, comprising a bottom plate, a sample pad, a combination pad, a coating film and an absorption pad, wherein the sample pad, the combination pad, the coating film and the absorption pad are fixed on the bottom plate in sequence along the flowing direction of a liquid sample to be detected; the binding pad is loaded with gold-labeled protein, wherein the gold-labeled protein comprises nCOVAg 01; the envelope film is provided with a detection area and a quality control area, the detection area is loaded with a mouse anti-human IgM/IgG antibody, and the quality control area is loaded with a goat anti-rabbit polyclonal antibody; nCOVAg01 includes the recombinant antigen.
The invention with the publication number of CN111426844A discloses a novel fluorescence immunochromatographic test strip for joint detection of coronavirus SARS-CoV-2 IgG-IgM antibodies, which comprises a bottom plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad, wherein the sample pad, the combination pad, the nitrocellulose membrane and the water absorption pad are sequentially connected end to end and pasted on the bottom plate, the combination pad is coated with SARS-CoV-2 structural protein-marker and goat anti-rabbit IgG-marker, and the nitrocellulose membrane is provided with a detection line T1 coated with mouse anti-human IgG monoclonal antibodies, a detection line T2 coated with mouse anti-human IgM monoclonal antibodies and a quality control line C coated with rabbit IgG.
Both of the above-mentioned prior arts are used for detecting whether human serum contains an antibody against SARS-CoV-2, and the in vivo antibody level is not used as a real-time diagnostic means because SARS-CoV-2 has been infected before.
Serological diagnosis is an accurate and efficient method for screening pathogens and has the advantage of good sample consistency. The monoclonal antibody provides powerful support for serological diagnosis, has the advantages of good specificity and high sensitivity in the serological diagnosis, is used for detecting whether a sample contains SARS-CoV-2, and can provide an accurate and rapid diagnosis means for prevention and control of novel coronavirus pneumonia.
The invention with publication number CN111303254A discloses an antibody against SARS-CoV-2, which specifically binds to the antigen; the antibody is a monoclonal antibody; the protein composed of any amino acid sequence shown in SEQ ID NO.2-SEQ ID NO.11 is used as an antigen, and is mixed with an adjuvant to prepare immunogen, and the immunogen is immunized with an animal to obtain an antibody. However, no specific information on antibodies is provided throughout this document, i.e. no corresponding antibody has actually been prepared in this prior art.
Disclosure of Invention
The invention provides a monoclonal antibody of anti SARS-CoV-2 nucleocapsid protein and its application.
A monoclonal antibody against SARS-CoV-2 nucleocapsid protein comprises light chain and heavy chain, wherein the amino acid sequences of the variable region CDR1, CDR2 and CDR3 of the light chain are RASENIYSSLA, VATDLA and QHFWGTPWT respectively; the heavy chain variable region CDR1, CDR2 and CDR3 have amino acid sequences of TDHYII, EIYPGNGHTYNERFKG and SRYYGPFAYWG, respectively.
Preferably, the monoclonal antibody has the amino acid sequence of the light chain variable region shown in SEQ ID No.4 and the amino acid sequence of the heavy chain variable region shown in SEQ ID No. 5.
Preferably, the monoclonal antibody is a full length antibody, a Fab antibody or a F (ab')2An antibody.
The invention also provides a gene encoding the monoclonal antibody. Preferably, the gene sequence encoding the variable region of the light chain is shown as SEQ ID number 2; the gene sequence for coding the heavy chain variable region is shown as SEQ ID number 3.
The invention also provides the application of the monoclonal antibody in preparing a kit for detecting SARS-CoV-2. Preferably, in the application, the detection mode is serological detection.
The invention also provides a kit for detecting SARS-CoV-2, comprising the monoclonal antibody. Preferably, the kit is an ELISA detection kit or an immunochromatography diagnostic kit using an immunochromatography test strip. More preferably, the sample to be tested is venous blood.
The monoclonal antibody of the invention for resisting SARS-CoV-2 nucleocapsid protein is IgG1 subtype, and the affinity of the antibody can reach 5.28X 10-11The kit has the advantages of strong immunocompetence, good stability, high activity, strong affinity and the like, has strong detection specificity, high sensitivity and good accuracy, can be used in a kit of a full-automatic immunoassay analyzer, is also applied to an immunochromatography test strip for detecting SARS-CoV-2 nucleocapsid protein, and can effectively promote the detection of SARS-CoV-2Popularization and application.
Drawings
FIG. 1 is a SDS-PAGE analysis of the SARS-CoV-2-N protein induced in example 1; m: and (3) protein Marker.
FIG. 2 is an SDS-PAGE analysis of the purified SARS-CoV-2-N protein of example 1.
FIG. 3 is an SDS-PAGE electrophoresis of the monoclonal antibody of example 2; m: protein Marker, 1: n10, 2: n15.
FIG. 4 is a graph showing the titer detection of monoclonal antibodies in example 3.
FIG. 5 is a graph showing the subtype identification of monoclonal antibodies in example 4.
FIG. 6 is a graph showing the affinity assay of the antibody in example 5.
Detailed Description
While the following is a description of the preferred embodiments of the present invention, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention. The experimental methods in the examples, in which specific conditions are not specified, are generally carried out under conventional conditions. In the examples of the present invention, unless otherwise specified, reagents and consumables used therein are commercially available.
Example 1: preparation of SARS-CoV-2-N recombinant protein
The gene sequence of the N protein is shown as SEQ ID NO: 1, designing primers as follows:
N-F: 5'-GCCGGATCCATGTCTGATAATGGACCCCAAAA-3' (with)BamHI cleavage site);
N-R: 5'-GCCGTCGACAGGCCTGAGTTGAGTCAGCAC-3' (with)SalI enzyme cutting site),
the primers are adopted, PCR is carried out by taking artificially synthesized N protein gene as a template, and the product is usedBamHI andSalafter the restriction enzyme I is subjected to double enzyme digestion, the DNA fragment is inserted into a pET-28a (+) prokaryotic expression vector which is subjected to the same two enzyme digestion treatments, and a recombinant plasmid pET28a-SARS-CoV-2-N inserted with an N protein gene sequence is obtained.
The correct plasmid of pET28a (+) -SARS-CoV-2-N expression vector for sequencing verification was transformed into E.coli BL21, spread on LB plate containing 100. mu.g/ml kanamycin sulfate, cultured overnight at 37 ℃, single colony was picked up, cultured with 300ml LB medium containing the same concentration of kanamycin sulfate at 37 ℃ until OD600 reached about 0.6, and induced to express with IPTG at final concentration of 0.4-1 mM at 25-37 ℃ and 250rpm for 5-8 h. After induction, the culture was centrifuged at 4 ℃ and 7000rpm for 10min to collect the cells. Centrifuging 1mL of culture solution, adding a sample buffer solution, boiling for 10min, and centrifuging to remove bacterial debris. SDS-PAGE analysis is carried out on the supernatant, the SARS-CoV-2-N fusion protein is expressed in the form of inclusion bodies, and the result is shown in figure 1, which shows that the fusion protein with higher purity is obtained.
The bacterial precipitation is dissolved by inclusion body combined buffer solution, protein purification nickel column is used for purifying recombinant SARS-CoV-2-N protein, urea solutions with different concentrations are used for elution and collection, SDS-PAGE detection shows that polyacrylamide gel electrophoresis is carried out when 300mM imidazole is used for elution, and the result is shown in figure 2, and a single target protein band with higher concentration appears at a 45KDa position.
The purified recombinant protein was dialyzed with dialysis buffer at 4 ℃ and the dialysate was changed every 12 hours. Taking out dialyzed protein solution, concentrating with polyethylene glycol-20000, and storing at-20 deg.C.
Example 2: preparation of SARS-CoV-2-N monoclonal antibody
The recombinant antigen SARS-CoV-2-N protein is used as immunogen, and when it is first immunized, 50-100 microgram of recombinant antigen SARS-CoV-2-N protein and equal volume of complete Freund's adjuvant are co-emulsified, and then the multipoint injection immunization is implemented under the subcutaneous skin of BALB/c mouse. The second time and the third time, 50-100 mug/recombinant antigen SARS-CoV-2-N protein is emulsified together with equal volume of incomplete Freund's adjuvant, and the immune interval is 15 days. After three immunizations, blood was collected from the tail vein of the mice, and the sera were separated and assayed for titer against the recombinant antigen SARS-CoV-2-N protein by indirect ELISA.
50-100 mu g/recombinant antigen SARS-CoV-2-N protein was injected into the abdominal cavity of mice 7d before cell fusion for boosting. Preparing feeder layer cells one day before fusion, taking one healthy mouse, separating spleen, preparing cell suspension, uniformly spreading the cell suspension in a cell plate, standing and culturing overnight to allow the cell to adhere to the wall. Spleen of immunized mice was isolated in sterile environment on the day of fusion, and cell suspension was prepared and mixed well in IMDM medium. The well-conditioned SP2/0 cells were compared with mouse splenocytes 1: 5-1: 10 mix, wash the mixed cells 3 times in serum-free IMDM medium preheated at 37 deg.C, discard the wash, add PEG1500 at 37 deg.C to fuse the cells. After centrifugation, 80mL of culture medium (IMDM 62mL, HAT 2mL, fetal bovine serum 16 mL) was added to the fused cells, mixed gently and mixed, and then added to a 96-well plate with feeder cells, and cultured in an incubator. In 11d fusion, titer detection was performed on the supernatants of the culture wells in which hybridoma cells grew by indirect ELISA, and two hybridoma cell lines with the highest positive values, N10 and N15, were obtained. The ELISA positive wells were subcloned 3 times by limiting dilution, and hybridoma cell lines were expanded and stored in liquid nitrogen.
Injecting paraffin oil into the abdominal cavity of BALB/c mouse of 8-10 weeks old, inoculating the recovered hybridoma cells after one week, wherein the inoculation amount is 1 × 106A/only. When the abdomen of the mouse is obviously enlarged, the ascites of the mouse is extracted by a sterile syringe, and the ascites is collected after centrifugation. The monoclonal antibody is precipitated and crude extracted by saturated ammonium sulfate solution, and SDS-PAGE electrophoresis is carried out to identify the purity of the antibody, the result is shown in figure 3, two monoclonal antibodies with numbers N10 and N15 clearly present two target bands at 55KDa and 25KDa, which shows that the monoclonal antibody against SARS-CoV-2-N with higher purity is successfully prepared.
Example 3: indirect ELISA method for detecting monoclonal antibody titer
The SARS-CoV-2-N protein purified in example 1 was coated at 1. mu.g/ml and 100. mu.l/well on an ELISA plate and incubated overnight at 4 ℃. The ELISA plates were washed with PBST, 200. mu.l/well of 5% nonfat dry milk was added, and blocked at 37 ℃ for 2 h. After washing, the monoclonal antibody of example 2 was added at a dilution of concentration by two at 1: 500, 1: 1000, 1: 2000, 1: 4000, 1: 8000, 1: 16000, 1: 32000, 1: 64000, 1: 128000, 1: 256000, 1: 512000, 1: 1024000, 100. mu.l/well, and incubated at 37 ℃ for 1 hour. After washing the plate, the appropriate dilution of horseradish peroxidase-labeled goat anti-mouse antibody was added and incubated at 37 ℃ for 1 h. Adding 100 mul/hole TMB chromogenic substrate for reaction for 10min, adding 50 mul 2mol/L sulfuric acid stop solution for stopping reaction, and reading OD value of each hole at 450nm by an enzyme-labeling instrument. The detection result is shown in figure 4, the titer of the anti-SARS-CoV-2-N protein monoclonal antibodies with the numbers N10 and N15 can reach 512000 and 1024000 respectively, and the antibody sensitivity is high.
Example 4: monoclonal anti-SARS-CoV-2-N protein subtype assay
The types of the monoclonal antibodies were identified using an ELISA rapid qualitative kit (reagent No. 062020, Jiangsu Bora enzyme immunoassay Biotech Co., Ltd.), and the results are shown in FIG. 5, and the anti-SARS-CoV-2-N monoclonal antibodies of Nos. N10 and N15 were determined by the heavy chain identification, and both monoclonal antibodies were of the IgG1 subclass.
Example 5: antibody affinity assay
Diluting recombinant antigen SARS-CoV-2-N protein, labeling with biotin, desalting with desalting column, wetting the end of SA sensor, and curing in the above antigen. The monoclonal antibody against SARS-CoV-2-N to be detected is diluted with PBS to the concentration of 0.3125nmol/L, 0.625nmol/L, 1.25nmol/L, 2.5nmol/L, 5nmol/L, 10nmol/L, 20nmol/L, and the total volume of each group of samples is 200 muL. Placing the diluted anti-SARS-CoV-2-N monoclonal antibody sample to be detected and blank control in a 96-well plate, and adopting ForteBio Octet Red biomolecule interaction instrument to detect the sample to be detected. The obtained data were analyzed by using Octet data analysis software CFR Part 11 Version 6.x, and affinity constants KD of the anti-SARS-CoV-2-N monoclonal antibodies with numbers N10 and N15 were obtained as 3.39X 10, respectively, after data fitting-11And 5.28X 10-11(FIG. 6).
Example 6: sequence analysis of monoclonal antibody encoding gene
The hybridoma cell RNA of the anti-SARS-CoV-2-N monoclonal antibody with the high affinity number N15 is extracted and reverse transcribed into cDNA. 2 pairs of degenerate primers are designed according to the constant regions of the heavy chain and the light chain of the antibody, PCR amplification is respectively carried out, and the target fragment is recovered and sequenced. The amino acid sequence of the light chain variable region obtained by analysis is shown as SEQ ID number 2, and the gene sequence of the coded light chain variable region is shown as SEQ ID number 4; the amino acid sequence of the heavy chain variable region is shown as SEQ ID number 3, and the gene sequence for coding the heavy chain variable region is shown as SEQ ID number 5.
Sequence listing
<110> Hangzhou college of medicine
<120> monoclonal antibody of anti SARS-CoV-2 nucleocapsid protein and application
<160> 13
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1258
<212> DNA
<213> Severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2)
<400> 1
atgtctgata atggacccca aaatcagcga aatgcacccc gcattacgtt tggtggaccc 60
tcagattcaa ctggcagtaa ccagaatgga gaacgcagtg gggcgcgatc aaaacaacgt 120
cggccccaag gtttacccaa taatactgcg tcttggttca ccgctctcac tcaacatggc 180
aaggaagacc ttaaattccc tcgaggacaa ggcgttccaa ttaacaccaa tagcagtcca 240
gatgaccaaa ttggctacta ccgaagagct accagacgaa ttcgtggtgg tgacggtaaa 300
atgaaagatc tcagtccaag atggtatttc tactacctag gaactgggcc agaagctgga 360
cttccctatg gtgctaacaa agacggcatc atatgggttg caactgaggg agccttgaat 420
acaccaaaag atcacattgg cacccgcaat cctgctaaca atgctgcaat cgtgctacaa 480
cttcctcaag gaacaacatt gccaaaaggc ttctacgcag aagggagcag aggcggcagt 540
caagcctctt ctcgttcctc atcacgtagt cgcaacagtt caagaaattc aactccaggc 600
agcagtaggg gaacttctcc tgctagaatg gctggcaatg gcggtgatgc tgctcttgct 660
ttgctgctgc ttgacagatt gaaccagctt gagagcaaaa tgtctggtaa aggccaacaa 720
caacaaggcc aaactgtcac taagaaatct gctgctgagg cttctaagaa gcctcggcaa 780
aaacgtactg ccactaaagc atacaatgta acacaagctt tcggcagacg tggtccagaa 840
caaacccaag gaaattttgg ggaccaggaa ctaatcagac aaggaactga ttacaaacat 900
tggccgcaaa ttgcacaatt tgcccccagc gcttcagcgt tcttcggaat gtcgcgcatt 960
ggcatggaag tcacaccttc gggaacgtgg ttgacctaca caggtgccat caaattggat 1020
gacaaagatc caaatttcaa agatcaagtc attttgctga ataagcatat tgacgcatac 1080
aaaacattcc caccaacaga gcctaaaaag gacaaaaaga agaaggctga tgaaactcaa 1140
gccttaccgc agagacagaa gaaacagcaa actgtgactc ttcttcctgc tgcagatttg 1200
gatgatttct ccaaacaatt gcaacaatcc atgagcagtg ctgactcaac tcaggcct 1258
<210> 2
<211> 348
<212> DNA
<213> mouse (Mus musculus)
<400> 2
gacattgtga tgacacagtc tccagcctcc ctatctgtat ctgtgggaga aactgtcacc 60
atcacatgtc gagcaagtga gaatatttac agtagtttag catggtatca gcagaaacag 120
ggaaaatctc ctcagctcct ggtctatgtt gcaactgact tagcagatgg tgtgccatca 180
aggttcagtg gcagtggatc aggcacacag tattccctca agatcaacag cctccagtct 240
gaagattttg ggagttatta ctgtcaacat ttttggggta ctccgtggac gttcggtgga 300
ggcaccaagc tggaaatcaa acgggctgat gctgcaccaa ctgtatcc 348
<210> 3
<211> 390
<212> DNA
<213> mouse (Mus musculus)
<400> 3
ttcacgagtc cagcctcaag cagtcaggtc caactgcagc agtctggacc tgatctggcg 60
aggcccgggg cttcagtgaa gctgtcctgc aaggcttctg gcgacacctt cactgaccac 120
tatataatct gggtgaagca gaggactgga cagggccttg aatggattgg agagatttat 180
cctggaaatg gtcatactta ctacaatgag aggttcaagg gcaaggccac actgactgca 240
gacgattcct ccagcacggc ctacatgcag ctcagcagcc tgacatctga ggactctgca 300
gtctatttct gtgcaagatc gaggtactac ggtccctttg cttactgggg ccaagggact 360
ctggtcactg tctctgcggc gcgcctagat 390
<210> 4
<211> 116
<212> PRT
<213> mouse (Mus musculus)
<400> 4
Asp Ile Gln Met Ile Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly
1 5 10 15
Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Ser
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
35 40 45
Tyr Val Ala Thr Asp Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Trp
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
100 105 110
Pro Thr Val Ser
115
<210> 5
<211> 130
<212> PRT
<213> mouse (Mus musculus)
<400> 5
Phe Thr Ser Pro Ala Ser Ser Ser Gln Val Gln Leu Gln Gln Ser Gly
1 5 10 15
Pro Asp Leu Ala Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala
20 25 30
Ser Gly Asp Thr Phe Thr Asp His Tyr Ile Ile Trp Val Lys Gln Arg
35 40 45
Thr Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Tyr Pro Gly Asn Gly
50 55 60
His Thr Tyr Tyr Asn Glu Arg Phe Lys Gly Lys Ala Thr Leu Thr Ala
65 70 75 80
Asp Asp Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser
85 90 95
Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Ser Arg Tyr Tyr Gly Pro
100 105 110
Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Arg
115 120 125
Leu Asp
130
<210> 6
<211> 11
<212> PRT
<213> mouse (Mus musculus)
<400> 6
Arg Ala Ser Glu Asn Ile Tyr Ser Ser Leu Ala
1 5 10
<210> 7
<211> 6
<212> PRT
<213> mouse (Mus musculus)
<400> 7
Val Ala Thr Asp Leu Ala
1 5
<210> 8
<211> 9
<212> PRT
<213> mouse (Mus musculus)
<400> 8
Gln His Phe Trp Gly Thr Pro Trp Thr
1 5
<210> 9
<211> 6
<212> PRT
<213> mouse (Mus musculus)
<400> 9
Thr Asp His Tyr Ile Ile
1 5
<210> 10
<211> 17
<212> PRT
<213> mouse (Mus musculus)
<400> 10
Glu Ile Tyr Pro Gly Asn Gly His Thr Tyr Tyr Asn Glu Arg Phe Lys
1 5 10 15
Gly
<210> 11
<211> 11
<212> PRT
<213> mouse (Mus musculus)
<400> 11
Ser Arg Tyr Tyr Gly Pro Phe Ala Tyr Trp Gly
1 5 10
<210> 12
<211> 32
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
gccggatcca tgtctgataa tggaccccaa aa 32
<210> 13
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
gccgtcgaca ggcctgagtt gagtcagcac 30

Claims (10)

1. A monoclonal antibody against SARS-CoV-2 nucleocapsid protein, comprising a light chain and a heavy chain, characterized in that the amino acid sequences of the variable region CDR1, CDR2 and CDR3 of the light chain are RASENIYSSLA, VATDLA and QHFWGTPWT respectively; the heavy chain variable region CDR1, CDR2 and CDR3 have amino acid sequences of TDHYII, EIYPGNGHTYNERFKG and SRYYGPFAYWG, respectively.
2. The monoclonal antibody of claim 1, wherein the light chain variable region amino acid sequence is set forth in SEQ ID No.4 and the heavy chain variable region amino acid sequence is set forth in SEQ ID No. 5.
3. The monoclonal antibody of claim 1, wherein the monoclonal antibody is a full length antibody, a Fab antibody, or a F (ab')2An antibody.
4. A gene encoding the monoclonal antibody according to any one of claims 1 to 3.
5. The gene of claim 4, wherein the gene encoding the light chain variable region has the sequence shown in SEQ ID No. 2; the gene sequence of the coding heavy chain variable region is shown in SEQ ID NO. 3.
6. Use of the monoclonal antibody of any one of claims 1 to 3 in the preparation of a kit for detecting SARS-CoV-2.
7. The use of claim 6, wherein the assay format is a serological assay.
8. A kit for detecting SARS-CoV-2, comprising the monoclonal antibody according to any one of claims 1 to 3.
9. The kit of claim 8, wherein the kit is an ELISA detection kit or an immunochromatographic diagnostic kit using an immunochromatographic test strip.
10. The kit of claim 9, wherein the sample to be tested is venous blood.
CN202011019047.4A 2020-09-24 2020-09-24 Monoclonal antibody for resisting SARS-CoV-2 nucleocapsid protein and application thereof Active CN112225797B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011019047.4A CN112225797B (en) 2020-09-24 2020-09-24 Monoclonal antibody for resisting SARS-CoV-2 nucleocapsid protein and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011019047.4A CN112225797B (en) 2020-09-24 2020-09-24 Monoclonal antibody for resisting SARS-CoV-2 nucleocapsid protein and application thereof

Publications (2)

Publication Number Publication Date
CN112225797A CN112225797A (en) 2021-01-15
CN112225797B true CN112225797B (en) 2022-01-25

Family

ID=74108118

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011019047.4A Active CN112225797B (en) 2020-09-24 2020-09-24 Monoclonal antibody for resisting SARS-CoV-2 nucleocapsid protein and application thereof

Country Status (1)

Country Link
CN (1) CN112225797B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021206638A1 (en) * 2020-04-09 2021-10-14 Intra-Immusg Private Limited Vaccine and/or antibody for viral infection
WO2021243417A1 (en) * 2020-06-05 2021-12-09 Centenary Institute Of Cancer Medicine And Cell Biology Immunogenic formulations
US20220056112A1 (en) * 2020-08-11 2022-02-24 Yurogen Biosystems Llc MONOCLONAL ANTIBODIES AGAINST SARS-CoV-2 NUCLEOCAPSID PROTEIN AND USES THEREOF
AU2021209282B2 (en) 2020-09-04 2022-06-02 Newsoara Biopharma Co., Ltd. Anti-Sars-Cov-2 Neutralizing Antibodies
CN112062840A (en) 2020-09-22 2020-12-11 石河子大学 Nano antibody based on novel coronavirus S protein and application thereof
AU2021209287B1 (en) 2021-01-19 2022-03-24 Newsoara Biopharma Co., Ltd. Expression Vector for Anti-Sars-Cov-2 Neutralizing Antibodies
CN113527474B (en) * 2021-03-12 2023-11-07 中国人民解放军军事科学院军事医学研究院 Monoclonal antibody of anti-novel coronavirus N protein and application thereof
CN113150133B (en) * 2021-03-15 2022-10-11 安源医药科技（上海）有限公司 Monoclonal antibodies against SARS-CoV-2 or antigen binding fragments thereof
CN113049817A (en) * 2021-03-17 2021-06-29 杭州启泰生物技术有限公司 Preparation method of novel coronavirus 2019-nCoV in-vitro diagnosis standard substance
CN113929773B (en) * 2021-10-08 2023-02-28 国际遗传工程和生物技术中心泰州区域研究中心 anti-SARS-CoV-2 S1-RBD monoclonal antibody and its application
CN117304310A (en) * 2021-12-13 2023-12-29 南京融捷康生物科技有限公司 SARS-Cov-2-N nano antibody and its derivative protein and application
CN116621976B (en) * 2023-07-04 2024-02-09 浙江大学 Monoclonal antibody 2H7 against PDCoV nucleocapsid protein and application method thereof
CN117143227B (en) * 2023-07-07 2024-03-12 广州海关技术中心 Specific antibody for combining coronavirus SARS-CoV-2 and SARS-CoV nucleocapsid protein and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111153991A (en) * 2020-02-26 2020-05-15 北京博奥森生物技术有限公司 Human SARS-CoV-2 monoclonal antibody and its preparation method and use
CN111303254A (en) * 2020-02-20 2020-06-19 北京新创生物工程有限公司 Novel coronavirus (SARS-CoV-2) antigen detection kit
CN111518203A (en) * 2020-05-27 2020-08-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) Kit for detecting novel coronavirus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303254A (en) * 2020-02-20 2020-06-19 北京新创生物工程有限公司 Novel coronavirus (SARS-CoV-2) antigen detection kit
CN111153991A (en) * 2020-02-26 2020-05-15 北京博奥森生物技术有限公司 Human SARS-CoV-2 monoclonal antibody and its preparation method and use
CN111518203A (en) * 2020-05-27 2020-08-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) Kit for detecting novel coronavirus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SARS-CoV-2抗体检测在新型冠状病毒肺炎诊断中的应用价值;汪建茹等;《检验医学》;20200630(第06期);全文 *
Structure of the SARA-Cov-2 spike receptor-binding domain bound to the ACE2 receptor;Jun Lan et al;《Nature》;20200330;第581卷;第215-221页 *
基于金标免疫层析技术SARS-CoV-2抗体检测COVID-19的临床应用价值分析;同重湘等;《兰州大学学报(医学版)》;20200408(第02期);全文 *

Also Published As

Publication number Publication date
CN112225797A (en) 2021-01-15

Similar Documents

Publication Publication Date Title
CN112225797B (en) Monoclonal antibody for resisting SARS-CoV-2 nucleocapsid protein and application thereof
KR102019008B1 (en) A method for detecting mers coronavirus using mers coronavirus nucleocapsid fusion protein
CN111704666B (en) Novel pairing monoclonal antibody of coronavirus N protein and application thereof
CN111366728A (en) Immunochromatography kit for detecting novel coronavirus SARS-CoV-2
CN113912710B (en) Monoclonal antibody for resisting novel coronavirus N protein and application thereof
CN115867573A (en) Epitope of antibody against SARS-CoV-2 structural protein, antibody reactive with the epitope, polypeptide containing the epitope, detection method, detection kit, vaccine, and therapeutic agent
CN116836270B (en) Monoclonal antibody of anti-bluetongue virus VP7 protein, preparation method and application
CN116693681B (en) Monoclonal antibody for resisting helicobacter pylori cytotoxin related protein A and application thereof
CN114702578B (en) Novel coronavirus Omicron mutant strain specific antibody and application thereof
CN111647055B (en) N protein for detecting novel coronavirus, preparation and application thereof
AU2009312731B2 (en) Antibodies to modified human IGF-1/E peptides
KR100832870B1 (en) Monoclonal antibody against nucleocapsid protein of SARS coronavirus and the use thereof
CN115286712A (en) Novel coronavirus Delta mutant strain specific antibody and application thereof
CN110938140A (en) Monoclonal antibody of Coxsackie virus A10 type solid virus and application thereof
CN117129675B (en) Reagent or kit for human bocavirus type specific detection or diagnosis
CN110938141B (en) Monoclonal antibody of coxsackievirus A6 type hollow virus and application thereof
CN110527668B (en) Toxoplasma gondii-resistant coryneform protein 4 (ROP 4) monoclonal antibody, and preparation method and application thereof
CN117126269A (en) Type 1 human bocavirus type specific antibody and application thereof
CN116449002A (en) Colloidal gold chromatographic test strip for screening vaccine immunity and novel coronavirus infection and application thereof
CN116143909B (en) anti-HIV-1P 24 antibody and preparation method and application thereof
CN110981955A (en) Monoclonal antibody of coxsackievirus A10 type hollow virus and application thereof
CN114349852B (en) anti-H3N 2 influenza virus hemagglutinin protein monoclonal antibody ZJU32-01 and application thereof in detection
CN113603786B (en) Bispecific antibodies that specifically bind SARS-CoV-2S protein and N protein
CN114702577A (en) Broad-spectrum antibody for recognizing West Nile virus and Zika virus E protein DIII
KR20110064174A (en) The anti-novel influenza a/h1n1-specific monoclonal antibodies for the diagnosis of novel flu and the diagnostic kits comprising the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant